Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, March 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2025 (2025-03-31): -361.19%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-227.52%
RETURN ON EQUITY (ROE) AVG 3Y
-131.40%
RETURN ON EQUITY (ROE) AVG 5Y
-114.02%
RETURN ON EQUITY (ROE) AVG 10Y
-129.59%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ocugen, Inc.
Market Cap
$352.67M
Return on Equity (ROE)
N/A
TTM Avg
-227.52%
3Y Avg
-131.40%
5Y Avg
-114.02%
Market Cap
$353.00M
Return on Equity (ROE)
N/A
TTM Avg
-12.63%
3Y Avg
-14.73%
5Y Avg
14.28%
Market Cap
$353.88M
Return on Equity (ROE)
-62.56%
TTM Avg
-108.31%
3Y Avg
-79.06%
5Y Avg
-57.33%
Market Cap
$355.36M
Return on Equity (ROE)
10.07%
TTM Avg
9.56%
3Y Avg
8.63%
5Y Avg
13.79%
Market Cap
$355.43M
Return on Equity (ROE)
-26.14%
TTM Avg
-53.80%
3Y Avg
-12.25%
5Y Avg
19.21%
Market Cap
$349.70M
Return on Equity (ROE)
-200.64%
TTM Avg
-134.16%
3Y Avg
-101.12%
5Y Avg
-54.69%
Market Cap
$346.73M
Return on Equity (ROE)
-1229.58%
TTM Avg
464.26%
3Y Avg
-581.37%
5Y Avg
-581.37%
Market Cap
$359.53M
Return on Equity (ROE)
-7.66%
TTM Avg
-10.18%
3Y Avg
260.20%
5Y Avg
144.75%
Market Cap
$344.04M
Return on Equity (ROE)
-29.98%
TTM Avg
-145.74%
3Y Avg
-129.76%
5Y Avg
-105.96%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocugen, Inc. (OCGN) | $352.67M | N/A | -227.52% | -131.40% | -114.02% |
| Embecta Corp. (EMBC)vs › | $353.00M | N/A | -12.63% | -14.73% | 14.28% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | -62.56% | -108.31% | -79.06% | -57.33% |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 10.07% | 9.56% | 8.63% | 13.79% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | -26.14% | -53.80% | -12.25% | 19.21% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | -200.64% | -134.16% | -101.12% | -54.69% |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | -1229.58% | 464.26% | -581.37% | -581.37% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | -7.66% | -10.18% | 260.20% | 144.75% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | -29.98% | -145.74% | -129.76% | -105.96% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | -589.37% | -290.01% | -205.39% |
ROE
N/A
ROA
-65.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-03-31 | -361.19% |
| 2024-12-31 | -182.42% |
| 2024-09-30 | -122.24% |
| 2024-06-30 | -286.02% |
| 2024-03-31 | -185.71% |
| 2023-12-31 | -151.86% |
| 2023-09-30 | -126.80% |
| 2023-06-30 | -119.88% |
| 2023-03-31 | -106.41% |
| 2022-12-31 | -109.96% |
| 2022-09-30 | -77.64% |
| 2022-06-30 | -55.06% |
| 2022-03-31 | -52.85% |
| 2021-12-31 | -60.91% |
| 2021-09-30 | -44.42% |
| 2021-06-30 | -40.63% |
| 2021-03-31 | -53.68% |
| 2020-12-31 | -101.26% |
| 2020-09-30 | -39.18% |
| 2020-06-30 | -122.75% |
| 2020-03-31 | -240.80% |
| 2019-12-31 | -209.12% |
| 2017-03-31 | -220.47% |
| 2016-12-31 | -119.47% |
| 2016-09-30 | -833.00% |
| 2016-06-30 | -251.25% |
| 2016-03-31 | -155.29% |
| 2015-12-31 | -113.57% |
| 2015-09-30 | -62.90% |
| 2015-06-30 | -60.76% |
| 2015-03-31 | -53.33% |
| 2014-12-31 | -42.05% |
| 2014-09-30 | -940.22% |
